ASTA Corporation Overview
ASTA is a small Korean developer and manufacturer of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometers. It is one of very few companies outside the global incumbents (Bruker, bioMérieux, Shimadzu) and a few Chinese entrants that builds the instrument, sample-preparation consumables and identification databases in-house. Its clinical franchise centres on the MicroIDSys microbial identification system, with a research-stage cancer-diagnostics platform (NosIDSys) alongside. Since 2018 it has repurposed the same time-of-flight core for industrial quality control: LDI-TOF systems for OLED display lines, battery-material analysis, and the GM-TOF real-time gas monitor for semiconductor fabs. Commercial traction remains very limited: revenue has stayed between KRW 2.6bn and 3.4bn for five years, with operating losses every year since listing. The company now depends on new equity, chiefly from SD Biosensor, whose pending takeover and distribution network are the core of any recovery case. That case is constrained by a revenue-recognition audit disclaimer and an unresolved delisting review.
What the company does. ASTA designs, manufactures and sells time-of-flight mass spectrometry systems and related consumables and software. Its founding technology is MALDI-TOF, a technique that ionises biomolecules (typically ribosomal proteins of bacteria and fungi) and identifies an organism by matching its mass "fingerprint" against a reference database. In clinical microbiology this replaces biochemical identification methods that take 8–48 hours with a test of a few minutes. The company's 2019 investor deck claimed identification in under five minutes at about USD 5 per sample, against USD 8–10 for conventional methods [S30].
Company's own description. Data-vendor summaries of ASTA's filings describe it as a developer of diagnostic solutions. They list microorganism identification systems (MicroIDSys, MicroIDSys Elite) for rapid infectious-disease diagnosis, food hygiene, agricultural and livestock quarantine and bio-terrorism prevention; the IDSys LT/RT MALDI-TOF platforms; NosIDSys for diagnosis of cancers and degenerative brain diseases; LDI-TOF for OLED analysis; disposable MALDI plates; a rapid enzyme digestion system; and diagnostic software [S37]. A July 2025 KOSDAQ technology analysis report describes ASTA as a developer of next-generation diagnostic and QC platforms built on proprietary MALDI-TOF technology. That report lists industrial products (LDI-TOF, GM-TOF, IDSys Premier) supplied to LG Display and others, and a Saudi joint venture (ASTA LLC) under Saudi Vision 2030 [S36].
Business model. The model is mainly a hardware-plus-consumables model:
Instrument sales: capital equipment sold to hospitals, research institutes, distributors and industrial customers.
Consumables: disposable MALDI plates (μFOCUS), sample-preparation kits (SepsiPrep, blood kits), magnetic beads and reagents.
Software and databases: microbial and cancer reference databases and AI and cloud diagnostic software. The company has promoted a cloud-connected MALDI-TOF platform linking instruments to a central data centre for remote diagnosis and disease surveillance [S25].
Government R&D grants: the company leads a KRW 4bn national display-process R&D project (2024) [S27].
ASTA does not publish a product/service/subscription/licensing revenue split. A 2011 licence-in of cancer-diagnostic technology from US firm Glycometrix is the only licensing arrangement identified [S30]. No subscription or recurring-software revenue has been disclosed.
Value-chain position. ASTA is vertically integrated across instrument design, core components, consumables and database development. The company has claimed it is the only firm that makes the analyser, its parts and its consumables in-house [S29]. Downstream it relies on distributors, both overseas (most sales, per a July 2025 company statement [S22]) and domestic hospital channels. The pending SD Biosensor transaction is meant to add a global distribution layer through SD Biosensor's overseas subsidiaries in nine countries [S8].
Customer types and end-markets.
Independent characterisation. ASTA is a technology-rich, commercially sub-scale company. It has spent nearly two decades building a credible MALDI-TOF capability, yet annual revenue has never exceeded KRW 3.4bn, and in FY2025 payroll alone (KRW 2.47bn) was 95.3% of revenue [S2]. Clinical microbiology is a high-barrier, incumbent-dominated market. Hospitals there buy on installed base and database breadth, and the Korean domestic market has historically preferred foreign products [S28]. The industrial QC pivot is technically interesting but has produced only "small but steady" annual shipments to large domestic firms [S26]. The financial history is defined by recurring equity raises, repeated going-concern pressure (capital impairment, revenue-threshold risk), and serious governance questions over related-party dealings. Those questions culminated in the FY2025 audit disclaimer over the substance and timing of certain FY2024–FY2025 sales [S9].
Strategy
Stated strategic themes (from company statements and filings as reported).
-
Clinical MALDI-TOF as a cloud-connected national diagnostic platform, linking instruments to central databases for remote diagnosis and disease surveillance. Saudi Arabia is the launch market [S25].
-
Saudi Arabia / Vision 2030 JV (ASTA LLC with SIIVC) for local manufacturing of medical and industrial instruments, aimed at the Middle East and North Africa. The plan is to mass-produce four medical models on the cloud platform in Saudi Arabia by 2030 [S25], [S31].
-
Industrial QC diversification into OLED, battery and semiconductor gas monitoring, using the same TOF core. Domestic semiconductor sales are the near-term focus, with Japan and Taiwan exports to follow [S26], [S28].
-
Partnership with SD Biosensor: SD Biosensor's global sales network is to be used to scale ASTA's equipment sales [S9], [S8].
Initiatives in the last 24 months.
ESG and cost programmes. No sustainability commitments or formal cost-reduction targets have been disclosed.
Guidance. ASTA does not issue formal guidance. Informal targets have consistently been missed: KRW 5bn revenue and a return to operating profit in 2022 [S31] (actual: KRW 3.3bn, KRW -2.8bn); KRW 10bn revenue in 2025 [S22] (actual: KRW 2.6bn). The Saudi JV has been described as a source of "explosive" growth since 2022 [S25], [S31] but has produced no disclosed revenue at scale. No medium-term targets exist for 2026–2027.
Products & Services
Prices are not publicly disclosed for any ASTA product.
Clinical diagnostics
| Product | Description | Key capabilities (company-stated) | Target customer | Launch / latest version | Source |
|---|---|---|---|---|---|
| MicroIDSys | MALDI-TOF microbial identification system: IDSys LT instrument, AutoPrep sample prep, AI software, microbial database | Bacterial ID accuracy above 99% (2017 claim); 10,000+ microbe records (2017); veterinary DB 1.0 with 619 species and 5,317 strains (2019); TB/NTM ID accuracy 95.5% (147 of 154); MRSA/MSSA accuracy 89–93% | Hospital microbiology labs, public health, food safety, quarantine, biodefence | Developed Jul 2015; launched Jun 2016 | [S29], [S30] |
| MicroIDSys Elite | Upgraded microbial identification system | Same application scope as MicroIDSys | Same | — | [S37] |
| IDSys LT | Linear-TOF MALDI platform tuned for diagnostics and polymer analysis; web-based software | CE-IVD (Dec 2016) | Clinical and research labs | Developed Jan 2014; launched Sep 2015 | [S30] |
| IDSys RT | Reflectron-TOF platform for disease and cancer diagnostic applications | Basis of NosIDSys | Research hospitals | Completed and launched Sep 2016 | [S30] |
| IDSys BT | Benchtop MALDI-TOF | Claimed performance comparable to floor-standing units with a much smaller footprint; paired with AutoPrep and antibiotic-susceptibility software/DB | Smaller labs | 2019 roadmap | [S30] |
| IDSys IM | MALDI imaging combined with near-infrared fluorescence microscopy | Tissue analysis; display-defect inspection | Research / industrial | Roadmap item (2019) | [S30] |
| NosIDSys | Cancer and degenerative-brain-disease diagnostic system on the RT platform | Ovarian/breast cancer DB of 2,000+ patients (2017); accuracy above 90% claimed; company says the technology could cover about 10 cancers, dementia and leukaemia as the DB grows | Research hospitals; prospective screening | Research use | [S29], [S30], [S36] |
| SepsiPrep Kit | Sample preparation from positive blood cultures | Identifies the causative organism within 2 hours of a positive blood culture, saving at least 2 days | Sepsis workflow in hospitals | Pre-2019 | [S30] |
| Blood kit | Blood sample preparation kit | — | Clinical labs | Commercialised Feb 2014 | [S30] |
| Cloud MALDI-TOF platform | Networked instruments linked to a central data centre holding cancer, microbe and virus data | Real-time remote diagnosis; regional and national disease monitoring; target uses include MERS/COVID-type infections, early cancer detection and antibiotic-resistance analysis | National health systems (Saudi focus) | Under development / deployment; cloud software being developed by related party CloudTOF | [S25], [S20] |
Industrial QC
| Product | Description | Key capabilities (company-stated) | Target customer | Launch / latest version | Source |
|---|---|---|---|---|---|
| LDI-TOF / OASys | Matrix-free laser desorption/ionisation TOF for OLED materials and contamination analysis | Pigment compounds in OLED panels act as the ionisation aid, so no matrix is needed; down to 2–3 µm resolution; material DB across the OLED process; one display line's defect rate reported to fall from 85% to 15% | OLED panel makers | Development from 2018; LG Display contract Oct 2021 | [S28], [S37] |
| Battery-analysis LDI-TOF | LDI-TOF configured for secondary-battery QC | Applied to EV battery inspection (2022) | Battery makers | 2022; LG Energy Solution contract reported | [S28], [S36] |
| GM-TOF | Real-time gas monitoring TOF system | Detects residual process gases (such as hydrogen fluoride) in real time, against imported sampling-type analysers; company says it shortens repair and consumable-replacement downtime that can otherwise take 2–3 weeks; described as the first such domestically developed analyser | Semiconductor fabs (Korea; Japan and Taiwan targeted) | ~10-month test on a memory maker's line; KSIA certification Mar 2026 | [S26], [S28] |
| IDSys Premier | Industrial MALDI/LDI platform | Supplied to LG Display and others per the KOSDAQ technology report | Display / electronics | — | [S36] |
| SDSys | TOF-based industrial QC system | Semiconductor and display process monitoring | Electronics manufacturers | Roadmap (2019) | [S30] |
| 3D imaging LDI TOF-MS (R&D) | Depth-resolved imaging MS for OLED nano-degradation analysis | Nanometre-scale depth resolution target | Display makers | Government project from 2024 (21 months) | [S27] |
Consumables, sample preparation and accessories
| Product | Description | Source |
|---|---|---|
| μFOCUS MALDI plate | Disposable hydrophobic-patterned target plate that uses less sample and matrix; the company says it made plates disposable that previously cost about USD 2,000 each | [S29], [S30] |
| REDS | Rapid Enzyme Digestion System for automated protein sample prep; Korean medical-device registration Aug 2013; patent Apr 2013 | [S30] |
| MALDI imaging matrix spotter | Matrix deposition for imaging MS (2011) | [S30] |
| Magnetic beads | Sample enrichment beads (2007) | [S30] |
| AutoPrep | Automated sample preparation paired with IDSys platforms | [S30] |
| Reference databases | Microbial, veterinary and cancer DBs | [S30] |
Financial Narrative
Income statement
Sources: [S1], [S3] (DART annual figures); EBITDA, FY2021–22 detail and diluted-EPS absence from [S4]; FY2024 pre-tax loss from [S22]. Diluted EPS equals basic EPS in every year because the company is loss-making. The FY2025 preliminary operating loss announced on 25 February 2026 was KRW 2,554,867,866, which the company described as a 36.4% improvement on FY2024 [S46].
Revenue CAGR FY2021–FY2025: about 0% (KRW 2.56bn in FY2021 [S4] against about KRW 2.59bn separate-basis revenue in FY2025 [S2]). Over a longer horizon, revenue went from KRW 0.2bn (FY2016) to KRW 1.7bn (FY2018) to a KRW 2.6–3.4bn plateau from FY2021 [S3].
Commentary. Revenue has stagnated in a narrow band for five years despite repeated management targets: a KRW 5bn target for 2022 with a return to operating profit [S31], and a KRW 10bn target for 2025 [S22]. Neither was met; FY2025 revenue fell 22.7%. Gross margin has swung between 21% and 50%. These swings reflect product mix (instruments vs. consumables vs. industrial systems) and fixed manufacturing-cost absorption at very low volume. Operating losses of KRW 2.6–4.0bn a year are structural. SG&A has run at roughly KRW 4bn or more annually [S22], and FY2025 payroll (KRW 2.47bn) equalled 95.3% of revenue [S2]. The operating-loss improvement in FY2025 was driven by cost movements rather than revenue growth. Its reliability is in question because the auditor flagged the substance and timing of certain FY2024–FY2025 sales [S9]. Revenue is heavily Q4-weighted (customers spending year-end budgets) [S22]. FY2024 Q4 alone was KRW 1.9bn of KRW 3.4bn, and the auditor's concerns centre on exactly this kind of period-end revenue.
Longer history (for context). FY2019 and FY2020 were dominated by non-operating write-downs: the KRW 8.4bn NorthQuest intangible impairment in FY2020 [S21] and losses in FY2019. Sources disagree on FY2019. DART-derived data show an operating loss of KRW 6.2bn and a net loss of KRW 15.0bn [S3], [S31], while S&P-sourced data show an operating loss of KRW 11.0bn and a net loss of KRW 10.7bn [S4]. The difference likely reflects classification of impairments. FY2020 net loss was KRW 11.1bn [S1].
Quarterly trend (most recent 10 quarters)
Source: [S1]. H1 2026 revenue was KRW 1.7bn (vs. KRW 0.8bn in H1 2025), with an operating loss of KRW 1.9bn and a net loss of KRW 2.3bn. Q2 2026 revenue rose 230% YoY from a very low base.
Balance sheet
Sources: FY2021–22 [S5]; FY2023 equity and capital [S22]; FY2024 [S24], [S22]. Goodwill: none reported. Net debt/cash in FY2022 was a net cash position of about KRW 2.7bn (cash and short-term investments of 4.2 less debt of 1.4) [S5].
Equity trajectory through 2025 (from press analysis of quarterly filings): equity of KRW 2.6bn at end-Q1 2025 (capital impairment ratio 61.76%, above the 50% KOSDAQ designation threshold); KRW 7.6bn at end-Q3 2025 after placements; about KRW 9.6bn pro forma after the 29 December 2025 placement. IB Tomato projected year-end FY2025 equity of about KRW 7.0bn if the usual quarterly loss recurred [S22], [S23]. Aggregator data imply a FY2025 ROE of -35.8% and ROA of -21.3% [S3].
Commentary. The balance sheet has been eroded by losses and then rebuilt by small placements, on a roughly annual cycle. Equity fell below paid-in capital in FY2023, reached a 39.71% capital impairment ratio at FY2024 year-end, and went past the 50% management-issue threshold at Q1 2025. Four placements in H2 2025 restored it [S22], [S23]. Cash at end-Q1 2025 (KRW 3.8bn including other current financial assets) was less than one year of SG&A [S22]. The February 2026 SD Biosensor placement (about KRW 10.5bn) is the largest single cash injection since the IPO era. It is also the first one large enough to fund more than a year of the current loss rate. Of the KRW 24bn SD Biosensor has paid so far on the share purchase, none went to ASTA; it went to the founders, who used much of it to repay high-interest loans [S9].
Cash flow
Sources: OCF, capex, FCF and D&A [S6]. Equity issuance: FY2021 from [S6] (IB Tomato reports the 2021 rights issue at KRW 5.0bn [S22]; the difference may include option exercises); FY2022–FY2024 from [S22]; FY2025 is the sum of the four 2025 placements (KRW 2.7bn + 1.0bn + 2.0bn + 2.0bn) [S23]. CB from [S23]. Over the five years to mid-2025, operating cash outflow averaged KRW 2.9bn a year [S22]; for the twelve months to September 2023 it was KRW -2.9bn [S6].
Commentary. ASTA burns roughly KRW 2–3bn of cash a year in operations, with negligible capex. Funding has come almost entirely from equity and, in 2025, a KRW 3.0bn convertible bond. In practice the company runs on a "raise to survive" model. Each year's placements roughly match the year's losses. The repeated discounted placements have diluted shareholders: the share count rose from about 12m (FY2021 average) to 16.38m now [S4], [S11].
Ratios
Sources: ROE and ROA [S3]; D/E and liabilities/equity computed from [S5], [S24]; impairment [S22]; payroll, revenue per employee and headcount [S2]. ROE, ROA and ROIC were deeply negative in all years. For the twelve months to September 2023, the aggregator reported ROE of -49.7%, ROA of -18.4%, ROIC of -23.7%, a current ratio of 7.23x, interest coverage of -9.4x and asset turnover of 0.36x [S7]. Net debt/EBITDA is not meaningful (negative EBITDA). A cash conversion cycle could not be computed. Inventory turnover of 0.92x (twelve months to September 2023) [S7] means inventory covers more than a year of cost of sales, which is typical of a low-volume instrument maker.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Functional Line Details
| Functional line (analyst-defined) | Contents | Status |
|---|---|---|
Clinical diagnostics | MicroIDSys / MicroIDSys Elite, IDSys LT/RT/BT, NosIDSys, SepsiPrep, databases, cloud software | Main historical revenue source; Saudi expansion planned |
Industrial QC | LDI-TOF / OASys (OLED), battery-material LDI-TOF, GM-TOF (semiconductor gas), IDSys Premier, SDSys | Small recurring shipments to large Korean groups |
Consumables and sample prep | μFOCUS MALDI plates, REDS, matrix spotter, magnetic beads, kits | Revenue scale not disclosed |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 3.1 | 3.4 | 2.6 |
Operating income (KRW Bn) | -2.7 | -4.0 | -2.6 |
Operating margin (%) | -86.9 | -119.8 | -99.8 |
Revenue YoY growth (%) | -6.3 | 7.1 | -22.7 |
Share of total revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Relationship | Status / notes | Source |
|---|---|---|---|
ASTA US (California) | Subsidiary, established January 2019 | — | [S30] |
ASTA LLC (Saudi Arabia) | JV with Saudi International Industrial Valley Company (SIIVC); ASTA targeted a 20% stake | — | [S31], [S25], [S36] |
NorthQuest | Former subsidiary (cancer DB / AI software); 59.71% sold October 2020 | Related party per press reporting | [S21] |
North Data | 100% owned by NorthQuest; held 3.6% of ASTA; borrower on loans secured by the CEO's ASTA shares | Related party | [S33], [S8] |
CloudTOF (formerly ASTA Innovations) | Set up by ASTA in June 2023, then transferred to a third party; ASTA staff involved in operations | Classified as a related party in ASTA's Q3 2024 report | [S20] |
Aquidas | Run by former ASTA CEO Ko Chung-gon; described in ASTA's report as a company run and controlled by the same management | Related party; borrowed KRW 820m in Q3 2024 | [S20] |
Intellect Galore Inc. | Buyer of the NorthQuest stake; led by Ko Chung-gon | Related party per press reporting | [S21] |
NQ Lab (엔큐랩) | Related party; borrower on a loan secured by Kim Yang-sun's ASTA shares | — | [S33] |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 2.6 | 3.3 | 3.1 | 3.4 | 2.6 |
Gross profit (KRW Bn) | 0.5 | 1.5 | 1.6 | 1.0 | 1.3 |
Operating income (KRW Bn) | -3.5 | -2.8 | -2.7 | -4.0 | -2.6 |
EBITDA (KRW Bn) | -2.6 | -2.0 | — | — | — |
Pre-tax income (KRW Bn) | — | — | — | -3.9 | — |
Net income (KRW Bn) | -3.5 | -2.8 | -2.8 | -3.9 | -3.3 |
EPS basic (KRW) | -305 | -221 | -217 | -289 | -234 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | 21.2 | 46.7 | 50.3 | 28.6 | 48.5 |
Operating margin (%) | -136.4 | -83.1 | -86.9 | -119.8 | -99.8 |
EBITDA margin (%) | -99.8 | -59.0 | — | — | — |
Net margin (%) | -137.8 | -83.7 | -89.8 | -115.2 | -127.3 |
Revenue YoY growth (%) | 103.2 | 30.5 | -6.3 | 7.1 | -22.7 |
Income Statement
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 0.4 | 0.7 | 0.4 | 1.9 | 0.4 | 0.4 | 1.1 | 0.8 | 0.5 | 1.2 |
Operating income (KRW Bn) | -1.3 | -1.0 | -0.8 | -0.8 | -1.6 | 0.0 | -0.5 | -0.5 | -1.1 | -0.8 |
Net income (KRW Bn) | -1.4 | -1.1 | -0.8 | -0.6 | -1.5 | -0.1 | -0.6 | -1.1 | -1.5 | -0.8 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Total assets (KRW Bn) | 11.1 | 10.9 | — | 8.6 |
Cash and equivalents (KRW Bn) | 2.9 | 3.2 | — | — |
Cash and short-term investments (KRW Bn) | 5.9 | 4.2 | — | — |
Receivables (KRW Bn) | 2.1 | 2.1 | — | — |
Inventory (KRW Bn) | 0.9 | 1.6 | — | — |
Total current assets (KRW Bn) | 9.0 | 7.9 | — | — |
PP&E (KRW Bn) | 1.2 | 2.3 | — | — |
Intangible assets (KRW Bn) | 0.5 | 0.4 | — | — |
Total debt incl. leases (KRW Bn) | 0.4 | 1.4 | — | — |
Total liabilities (KRW Bn) | 2.2 | 3.7 | — | 4.4 |
Shareholders' equity (KRW Bn) | 8.9 | 7.2 | 6.2 | 4.1 |
Paid-in capital (KRW Bn) | — | — | 6.6 | 6.8 |
Working capital (KRW Bn) | 8.5 | 6.8 | — | — |
Book value per share (KRW) | 702 | 561 | — | — |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | -1.1 | -1.6 | — | — | — |
Capital expenditure (KRW Bn) | -0.1 | -0.2 | — | — | — |
Free cash flow (KRW Bn) | -1.2 | -1.8 | — | — | — |
Equity issued (KRW Bn) | 6.0 | 1.0 | 1.3 | 2.0 | 7.7 |
Convertible bonds issued (KRW Bn) | 0 | 0 | 0 | 0 | 3.0 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Depreciation and amortisation (KRW Bn) | 1.0 | 0.8 | — | — | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | — | -35.8 |
ROA (%) | — | — | — | — | -21.3 |
Debt to equity (x) | 0.04 | 0.20 | — | — | — |
Liabilities to equity (x) | 0.24 | 0.51 | — | 1.07 | — |
Capital impairment ratio (%) | — | — | — | 39.71 | — |
Payroll as % of revenue | 61.6 | 40.7 | 51.0 | 54.9 | 95.3 |
Revenue per employee (KRW Mn) | 88.4 | 110.0 | 97.9 | 110.0 | 68.3 |
Employees (year-end) | 29 | 30 | 32 | 30 | 38 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 3.1 | 3.4 | 2.6 |
Share Price & Returns
| Reference point | Price (KRW) |
|---|---|
IPO (Mar 2017) | 8,000 |
All-time intraday high (19 Jan 2018) | 27,913 |
Early Jan 2024 close | 5,320 |
CB issue reference, 5 Mar 2025 | 5,180 |
Late Dec 2025 / early Jan 2026 | 8,320 |
SD Biosensor purchase price (Feb 2026) | 7,950 |
SD Biosensor subscription price (Feb 2026) | 8,720 |
Last trade before suspension (24 Mar 2026) | 6,070 |
52-week range (as of Aug 2026) | 5530 – 11080 |
Valuation Snapshot
| Multiple | Value | Basis | Source |
|---|---|---|---|
Market cap | KRW 99.4bn | 16,381,300 shares | [S38], [S11] |
P/E | n/m | Loss-making | — |
P/S (trailing FY2025) | about 38x | KRW 99.4bn / KRW 2.6bn | Computed from [S1] |
P/B | 9.99x | Aggregator, FY2025 book | [S3] |
EV/EBITDA | n/m | Negative EBITDA | — |
Capital Markets
| Item | Detail | Source |
|---|---|---|
Analyst consensus | None (no sell-side coverage identified) | [S37] |
Dividends | None paid in history | [S3], [S7] |
Buybacks | None authorised | — |
Credit ratings | None (Moody's / S&P / Fitch: not rated) | — |
Other debt | Lease liabilities of about KRW 1.2bn (FY2022); bank borrowings not significant in FY2021–FY2022 | [S5] |
Equity raises (FY2021 → FY2025, KRW Bn) | 6.0 → 1.0 → 1.3 → 2.0 → 7.7, plus 10.46 in Feb 2026 | [S6], [S22], [S23], [S44] |
Share Count (millions)
| Metric | FY2021 | FY2022 | FY2025 |
|---|---|---|---|
Shares outstanding, year-end (millions) | — | — | 15.18 |
Shares outstanding, weighted average (millions) | 12 | 13 | — |
Analyst Conclusions
Management guidance. No formal guidance is in force. The company's stated priorities are to resolve the revenue-recognition issue through re-audit, recover operating performance, and then complete the SD Biosensor transaction. Management has explicitly tied the deal timing to avoiding a premature substantive listing review [S9]. There is no consensus, since no analysts cover the stock.
Bull case.
-
Strategic owner in place. SD Biosensor has already committed about KRW 34.5bn (KRW 24bn to sellers plus KRW 10.46bn of new equity) [S8], [S11]. That is a strong incentive to see the relisting through and to push ASTA instruments through its nine-country network.
-
Industrial QC traction. KSIA certification of GM-TOF after a 10-month fab test [S26], plus existing LG Display and LG Energy Solution relationships [S28], give a credible path to higher-value, repeat industrial orders that do not depend on hospital adoption.
-
Operating improvement signs. The FY2025 operating loss narrowed 36% [S46], and Q2 2026 revenue rose 230% YoY [S1]. With KRW 10bn+ of new cash, the company has its longest funding runway in years.
Bear case.
-
Listing risk is binary. A failed re-audit by April 2027 would likely mean delisting, given the disclaimer centres on revenue substance [S9], [S13].
-
Deal risk. Closing has slipped three times, and SD Biosensor's own FY2025 operating loss (KRW -80.9bn) [S41] may reduce its appetite. The KRW 8.81bn balance is still unpaid [S11].
-
No evidence of scale. Five years of flat revenue at KRW 2.6–3.4bn despite repeated targets [S1], [S22], [S31]. A history of related-party value leakage [S20], [S21] means even a successful relisting leaves a weak earnings base.
Key catalysts and monitorables (next 12 months).
-
Re-audit of the FY2025 statements and any restatement of FY2024–FY2025 revenue
-
KRX decision after the improvement period (around April 2027) and any substantive-review trigger
-
Closing (or termination) of the SD Biosensor SPA by 15 December 2026; election of SD Biosensor directors
-
FY2026 audit opinion (audit report due around March 2027)
-
Conversion or redemption of the KRW 3.0bn CB
-
Saudi JV construction and capitalisation; Saudi FDA approval status
-
GM-TOF purchase orders from Korean, Japanese or Taiwanese fabs
-
Q3 2026 results (due around mid-November 2026)
Analyst verdict. ASTA is best understood as a distressed technology asset waiting on a rescue, not as an operating growth story. Its technical credentials are real. It built a medical-grade MALDI-TOF platform domestically, secured Korean and CE approvals in 2015–2016, and has since placed its time-of-flight systems with demanding industrial customers, most recently earning a semiconductor-fab performance certification for GM-TOF. Those achievements have never turned into a business of meaningful size. Revenue has stalled at KRW 2.6–3.4bn for five years, operating losses have consumed most of each year's revenue, and the company has survived on a cycle of small, discounted equity placements.
The FY2025 disclaimer of opinion changes the risk profile in kind, not just degree. The auditor's concern goes to whether certain recent sales were real and correctly timed. That calls into question the revenue base investors would use to value any recovery. It also follows a documented history of transactions with management-linked entities that moved value away from minority shareholders. Until a clean re-audit is obtained, historical and current-year financials should be treated as provisional.
The most important positive is SD Biosensor. A well-capitalised diagnostics group has already put substantial cash at risk and has every reason to see a remediation through. If the re-audit succeeds, the deal closes, and SD Biosensor installs governance and distribution, ASTA could become a useful capability inside a larger group. In that scenario, the value to public minority holders would depend on the post-relisting liquidity and terms. If the re-audit fails, delisting is the likely outcome, whatever the technology's merit. On balance, the risk is asymmetric to the downside for minority investors over the next twelve months, and the key evidence to watch is the re-audit outcome and the December 2026 closing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Background | Tenure / notes | Source |
|---|---|---|---|---|
Jo Eung-joon (조응준) | CEO and Chairman; largest shareholder (18.52%) | Former president of Green Cross; founder of ASTA | CEO in FY2025 filings; agreed in February 2026 to sell his entire stake to SD Biosensor and step back from management on closing | [S2], [S29], [S8] |
Kim Yang-sun (김양선) | Vice-Chairman; co-founder; spouse of the CEO | Former senior researcher at the Korea Research Institute of Standards and Science; former professor at Semyung University; former director of Hanyang University's Biochip Center | Co-CEO at IPO (2017); selling 1,094,037 shares to SD Biosensor and keeping 1,000,000 shares (6.10%), whose voting rights are delegated to SD Biosensor on request | [S29], [S17], [S15] |
Ko Chung-gon (고충곤) | Former CEO | Heads Intellect Galore and Aquidas (related parties) | Co-developed an infectious-disease diagnostic platform patented in 2021 under Intellect Galore's name with Jo Eung-joon | [S21] |
Park Yun-cheol (박윤철) | Executive Director (2022) | Industrial QC business | Quoted in 2022 | [S28] |
Shin Dong-jin (신동진) | Executive Director, head of R&D Division 1 (2022) | — | Quoted in 2022 | [S28] |
Park Chul-woo (박철우) | Officer; holds 0.35% | — | FY2025 | [S2] |
Park Jong-wan (박종완) | Officer; holds 0.33% | — | FY2025 | [S2] |
Jang Heon-cheol (장헌철) | Former director | Head of Loft Management (sold NorthQuest shares to ASTA in 2019) | — | [S21] |
Major Shareholders
| Holder | Stake (%) | Basis / date | Source |
|---|---|---|---|
Jo Eung-joon | 18.52 | 3,033,167 shares on 16,381,300 shares (Sep 2026 filing); 20.34% at FY2025 year-end | [S11], [S2] |
Kim Yang-sun | 12.78 | 2,094,037 shares (Sep 2026 filing); 14.04% at FY2025 year-end | [S11], [S2] |
Other related parties (two officers, CEO's sibling) | 0.73 | FY2025 year-end | [S2] |
Largest shareholder group total | 35.11 | FY2025 year-end | [S2] |
SD Biosensor — shares owned | 7.33 | 1,200,000 new shares (Feb 2026 placement) | [S11] |
SD Biosensor — reported holding incl. contractual rights | 38.62 | 5%-holder report filed 23 June 2026 (includes contracted shares and voting proxy) | [S2], [S15] |
SD Biosensor — on closing | 32.52 | 5,327,204 shares | [S11] |
Poome Asset Management (품에자산운용) | 5.27 | Report of 1 July 2025 (via KB Securities trust placement) | [S2], [S22] |
Minority shareholders | 45.43 | 3,697 holders, FY2025 year-end | [S2] |
Competitive Landscape
Key Competitors
| Competitor | Country | Relevant product(s) | Positioning vs. ASTA | Source / basis |
|---|---|---|---|---|
Bruker | US/Germany | MALDI Biotyper (clinical microbiology) | Global category leader; very large installed base and database | [S40]; ASTA deck names Bruker as a primary rival [S30] |
bioMérieux | France | VITEK MS / VITEK MS PRIME | Global microbiology leader; integrated workflow with ID/AST; internalised VITEK MS PRIME manufacturing in 2025 | [S39], [S30] |
Shimadzu | Japan | MALDI-TOF hardware (historically partnered with bioMérieux on VITEK MS) | Strong instrument maker | [S30], [S29] |
Becton, Dickinson | US | Microbiology systems (historically co-marketed Bruker MALDI) | Major microbiology-lab channel | [S42]; analyst identification |
Thermo Fisher Scientific | US | Microbiology identification portfolio | Broad lab supplier | [S42] |
Autobio Diagnostics | China | Autof MALDI-TOF microbial ID | Low-cost Chinese competitor; relevant to ASTA's China and emerging-market ambitions | Analyst identification (not company-disclosed) |
Zybio | China | EXS-series MALDI-TOF | Low-cost Chinese competitor | Analyst identification |
Bioyong Technologies | China | Clin-ToF microbial ID | Low-cost Chinese competitor | Analyst identification |
Imported residual-gas / sampling gas analysers (e.g., INFICON, MKS Instruments) | Switzerland / US | Fab gas monitoring | Incumbents in GM-TOF's target market; ASTA claims a real-time advantage | [S26] (incumbents unnamed in source); analyst identification |
TOF-SIMS / surface-analysis vendors (e.g., IONTOF, Physical Electronics) | Germany / US | OLED and materials surface analysis | Alternatives to LDI-TOF in display QC | Analyst identification |
Peer Comparison FY2025
| Company | FY | Revenue | Growth | Operating margin | R&D intensity | Source |
|---|---|---|---|---|---|---|
ASTA | FY2025 | KRW 2.6bn | -22.7% | -99.8% | — | [S1], [S3] |
Bruker | FY2025 | USD 3,436.5m | +2.1% reported; -3.7% organic | 2.0% GAAP; 12.6% non-GAAP | — | [S40] |
bioMérieux | FY2025 | EUR 4,070m (microbiology EUR 1,339m) | +2.3% reported; +6.2% organic (microbiology +4.2% like-for-like) | 17.9% contributive operating margin | 12.5% | [S39] |
SD Biosensor (pending parent) | FY2025 | KRW 710.6bn | +2.3% | -11.4% | — | [S41] |
Recent Developments
Pre-window context: the first Saudi orders (Feb 2025) [S25] and the KRW 3.0bn CB to Sangsangin Securities (6 Mar 2025) [S23].



